Carl Zeiss Meditec AG (XSWX:AFX) 1-Year Sharpe Ratio: -1.00 (As of Jul. 11, 2026)


XSWX:AFX Carl Zeiss Meditec AG XSWX:AFX
70 GF Score
Price CHF26.30
GF Value CHF314.62
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG 1-Year Sharpe Ratio?

Carl Zeiss Meditec AG XSWX:AFX 70 1-Year Sharpe Ratio is -1.00 as of Jul. 11, 2026. GuruFocus rates XSWX:AFX with a GF Score™ of 70/100 and a GF Value™ of CHF314.62 (Significantly Undervalued). The stock has 4 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-11), Carl Zeiss Meditec AG's 1-Year Sharpe Ratio is -1.00.

Carl Zeiss Meditec AG  (XSWX:AFX) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Carl Zeiss Meditec AG 1-Year Sharpe Ratio Related Terms

XSWX:AFX vs ISRG, BDX, MDLN: 1-Year Sharpe Ratio Comparison

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Carl Zeiss Meditec AG 1-Year Sharpe Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's 1-Year Sharpe Ratio falls into.


XSWX:AFX
70GF Score
Carl Zeiss Meditec AG XSWX:AFX
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -1.00 mean?
Carl Zeiss Meditec AG (XSWX:AFX) has a 1-Year Sharpe Ratio of -1.00 as of Jul. 11, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's 1-Year Sharpe Ratio too high?
Carl Zeiss Meditec AG's current 1-Year Sharpe Ratio is -1.00. Overall, Carl Zeiss Meditec AG has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's 1-Year Sharpe Ratio compare to ISRG and BDX?
Carl Zeiss Meditec AG's 1-Year Sharpe Ratio of -1.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Devices & Instruments company?
A good 1-Year Sharpe Ratio depends on the Medical Devices & Instruments industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current 1-Year Sharpe Ratio is -1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF314.62, compared to a current price of CHF26.30 — trading 91.6% below its estimated fair value. The current 1-Year Sharpe Ratio is -1.00. Carl Zeiss Meditec AG's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current 1-Year Sharpe Ratio is -1.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of CHF26.30 is trading 91.6% below its estimated GF Value™ of CHF314.62. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for XSWX:AFX:

  • 1-Year Sharpe Ratio: -1.00
  • GF Value™: CHF314.62 vs. price of CHF26.30 (91.6% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
70GF Score

Get the complete analysis for XSWX:AFX

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.30
Price
CHF314.62
GF Value